Start with the counterintuitive number: at the peak of the mRNA vaccine moment, a large share of mRNA filings weren't about vaccine sequences at all. They were about the delivery vehicle and how to manufacture it.
The reason is structural. An mRNA sequence is relatively easy to design and easy to change — which also makes it harder to defend as a durable, differentiated asset. The lipid nanoparticle that carries it, and the process that makes it consistently, are the harder problems and the stickier patents.
The filing record bears that out. Manufacturing claims like US20210275689A1 (processes of preparing mRNA-loaded lipid nanoparticles) and stability claims like US20210046192A1 cluster heavily in 2021. These are process patents, not sequence patents.
Application breadth shows up in parallel. Publication US20210386843A1, an mRNA vaccine filing, reaches toward cancer-relevant antibody targets — the same technology aimed beyond infectious disease. When delivery, manufacturing, and non-vaccine applications all spike together, that's a platform being built, not a single product.
The standard caution: filing volume measures investment and intent, not revenue. A surge in delivery patents tells you where the smart money thought the moat was — it doesn't guarantee those moats hold or pay off.
By the numbers, though, the 2021 mRNA story is clear: the vaccine was the headline, but the patent center of gravity was in the envelope and the factory. That's where the field expected the durable value to sit.